Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

Intellia and Kyverna announce CAR-T pact

By Brian Buntz | January 5, 2022

Kyverna/IntelliaGenome editing company Intellia Therapeutics (NSDQ:NTLA) and cell therapy firm Kyverna Therapeutics have entered into a licensing and collaboration agreement to develop an allogeneic CD19 chimeric antigen receptor (CAR) T-cell therapy for various B cell-mediated autoimmune diseases.

Under the terms of the agreement, Intellia (Cambridge, Massachusetts) will get an equity stake in Kyverna (Emeryville, California) and has made an additional investment in the company. In exchange, Kyverna will get exclusive rights to use Intellia’s platform to develop KYV-201, an investigational CD19 CAR-T cell therapy.

Under the deal, Intellia also can exercise an option to manage U.S. commercialization activities related to KYV-201 in partnership with Kyverna. In such an arrangement, Intellia would pay an opt-in fee and cover half of the development costs while sharing half of the future U.S. revenue related to the drug. Additionally, Intellia would also get royalties on net sales outside of the U.S.

“Intellia has built a novel CRISPR/Cas9-based allogeneic platform with the goal of developing safer and more effective therapies for a host of diseases. We are excited to license our allogeneic cell engineering platform to Kyverna for the development of a new autoimmune disease therapeutic product for patients,” said Intellia President and CEO Dr. John Leonard in a statement.

In related news, Kyverna recently inked a deal with the NIH to obtain exclusive rights to a clinical-stage anti-CD19 chimeric antigen receptor T-cell therapy. That agreement gives Kyverna rights to develop both autologous and allogeneic CAR T-cell therapies.

 


Filed Under: Drug Discovery, Drug Discovery and Development, Oncology
Tagged With: CD19 chimeric antigen receptor, Intellia Therapeutics, Kyverna Therapeutics
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Lab facility
Massachusetts is competing for ARPA-H biomedical research center
Blockchain
Startup vies to get blockchain adoption in pharma off the ground
Black Diamond Therapeutics
Black Diamond analysis highlights 22 new oncogenic HER2 driver mutations
NIH National Institutes of Health
NIH licenses COVID-19 research technologies to WHO initiative

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50